From Wikipedia, the free encyclopedia
Jump to: navigation, search
Protein PDE4B PDB 1f0j.png
Available structures
PDB Human UniProt search: PDBe RCSB
Aliases PDE4B, DPDE4, PDEIVB, phosphodiesterase 4B
External IDs MGI: 99557 HomoloGene: 1953 GeneCards: 5142
Genetically Related Diseases
Disease Name References
lymphoblastic leukemia
RNA expression pattern
PBB GE PDE4B 203708 at tn.png

PBB GE PDE4B 211302 s at tn.png

PBB GE PDE4B gnf1h03574 at tn.png
More reference expression data
Species Human Mouse
RefSeq (mRNA)


RefSeq (protein)


Location (UCSC) Chr 1: 65.79 – 66.37 Mb Chr 4: 102.09 – 102.61 Mb
PubMed search [2] [3]
View/Edit Human View/Edit Mouse

cAMP-specific 3',5'-cyclic phosphodiesterase 4B is an enzyme that in humans is encoded by the PDE4B gene.[1]

This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.[1][2]

Clinical relevance[edit]

Altered activity of this protein has been associated with schizophrenia and bipolar disorder.[1] PDE4B is believed to be the PDE4 subtype involved in the antipsychotic effects of PDE4 inhibitors such as rolipram.[3] PDE4B is involved in dopamine-associated and stress-related behaviours.[4] It has also recently been implicated in Alzheimer's disease.[5]


AN2728, a boron-containing drug candidate that as of 2015 was under development by Anacor Pharmaceuticals for the topical treatment of psoriasis and atopic dermatitis (atopic eczema).[6][7][8] mainly acting on PDE4B.[8]


  1. ^ a b c "Entrez Gene: PDE4B phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)". 
  2. ^ Swerdlow, Neal R. (2010-08-19). Behavioral Neurobiology of Schizophrenia and Its Treatment. Springer Science & Business Media. ISBN 9783642137174. 
  3. ^ Porteous DJ, Millar JK, Brandon NJ, Sawa A (Dec 2011). "DISC1 at 10: connecting psychiatric genetics and neuroscience". Trends in Molecular Medicine 17 (12): 699–706. doi:10.1016/j.molmed.2011.09.002. PMC 3253483. PMID 22015021. 
  4. ^ Francis, SH; Conti, M; Houslay, MD, eds. (2011). Phosphodiesterases as Drug Targets (PDF). Handbook of Experimental Pharmacology 204. Springer Berlin Heidelberg. doi:10.1007/978-3-642-17969-3. ISBN 978-3-642-17968-6. 
  5. ^ http://newsdaily.com/2015/08/scientists-researching-brain-disorders-create-super-clever-mice/
  6. ^ Anacor AN2728 at Anacor website Page accessed May 15, 2015
  7. ^ Nazarian R, Weinberg JM (Nov 2009). "AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis". Current Opinion in Investigational Drugs 10 (11): 1236–42. PMID 19876791. 
  8. ^ a b Moustafa F, Feldman SR (May 2014). "A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology". Dermatol Online J. 20 (5): 22608. PMID 24852768. 

Further reading[edit]